<DOC>
	<DOCNO>NCT00393380</DOCNO>
	<brief_summary>The purpose study determine whether addition parathyroid hormone sequential cord blood transplant improve engraftment , ability transplant stem cell grow successfully begin produce new blood cell .</brief_summary>
	<brief_title>Study Parathyroid Hormone Following Sequential Cord Blood Transplantation From Unrelated Donor</brief_title>
	<detailed_description>In phase II , single stage study , participant include 40 adult candidate hematopoietic stem cell transplant . All participant undergo sequential cord blood transplant use well-known myeloablative regimen fludarabine , cyclophosphamide , total body irradiation , appropriate individual likely benefit ablative regimen . Tacrolimus combine mycophenolate mofetil ( MMF ) graft-versus-host disease ( GVHD ) prophylaxis regimen . Parathyroid hormone ( PTH ) add regimen attempt improve engraftment . PTH approve drug minimal side effect individual osteoporosis ; dose PTH determined phase I study individual hematologic cancer .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>One follow diagnosis : 1 . Chronic myelogenous leukemia ( CML ) accelerate phase second stable phase ; individual first chronic phase eligible resistance imatinib 2 . Myelodysplasia 3 . Aplastic anemia respond immunosuppressive therapy 4 . Myelofibrosis , either primary secondary polycythemia vera 5 . Relapsed lymphoma Hodgkin 's disease 6 . Stage III/IV chronic lymphocytic leukemia ( CLL ) , relapse refractory least one fludarabine contain regimen 7 . Acute myelogenous leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) complete remission ( CR ) 2 great , CR 1 high risk feature No prior autologous stem cell transplant Eastern Cooperative Oncology Group ( ECOG ) performance status le 2 Lack 6/6 5/6 match related donor OR lack 10/10 match unrelated donor OR available donor appropriate time frame perform potentially curative stem cell transplant Diffusing capacity lung carbon monoxide ( DLCO ) great 50 % predict value Left ventricular ejection fraction ( LVEF ) great 50 % predict value Calcium level less 10.5 mg/dl Phosphate level great 1.6 mg/dl Heart disease , determine symptomatic congestive heart failure , radionuclide ventriculogram ( RVG ) , echocardiogramdetermined LVEF le 50 % , active angina pectoris , uncontrolled high blood pressure Pulmonary disease , determine severe chronic obstructive lung disease , symptomatic restrictive lung disease , correct DLCO le 50 % predict value Kidney disease , determine serum creatinine level great 2.0 mg/dl Liver disease , determine serum bilirubin level great 2.0 mg/dl ( except case Gilbert 's syndrome hemolytic anemia bilirubin elevate great 2.0mg/dl ) , SGOT SGPT great 3 time upper limit normal Neurologic disease , determine symptomatic leukoencephalopathy , active central nervous system ( CNS ) cancer , neuropsychiatric abnormality may prevent transplantation ( previous CNS cancer presently CR acceptable ) HIV antibody Uncontrolled infection Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Myelogenous Leukemia , Chronic</keyword>
	<keyword>Myelodysplasia</keyword>
	<keyword>Parathyroid Hormone</keyword>
	<keyword>Umbilical Cord Blood Stem Cell Transplantation</keyword>
</DOC>